Tsai Philip

CTO Philip Tsai buys 10,000 shares of IMNM at $20.49; holdings rise to 43.3K (+30.0%); stock up +18.9% in 30 days, +108.6% in 90 days.

Philip Tsai, Chief Technical Officer, purchased 10,000 shares at $20.49 on 2025-12-19, increasing his holdings by 30.0% to 43.3K shares. His two prior buys at IMNM both generated positive 90-day returns (+1.0% and +16.3%), and his cross-ticker track record shows a 100.00% 90-day win rate across 2 prior buys. The current stock has risen +18.9% in 30 days and +108.6% in 90 days from his transaction date, consistent with his historical timing pattern. However, the company faces material headwinds: revenue was $0.00 in the latest quarter, net income was $-57.5M in the most recent full year, and annual revenue growth contracted by -35.5%, indicating significant operational stress despite the sharp recent price appreciation.

CTO Tsai Philip buys 12,300 shares of IMNM at $8.42, now 58.6% above entry price ($6.95 current), while company faces -35.5% revenue decline and $-47.1M net loss.

Tsai Philip, Chief Technology Officer, purchased 12,300 shares at $8.42 on 2025-03-24, increasing his holdings from 21,000 to 33,300 shares. The purchase came at $8.42 per share, which is $1.47 above the current price of $6.95, and well above the 52-week low—a $16.57 disconnect from the 52-week high of $25.52. The broader context shows Immunome faces material headwinds: annual revenue declined 35.5% to $2,910,000 in the latest quarter, and the company posted a net loss of $-47,100,000 for its most recent full fiscal year. Tsai's prior buy at this ticker on 2024-11-21 delivered +5.0% after 90 days, consistent with his cross-ticker open-market history (100% win rate, +5.0% avg 90d return). The timing of this purchase relative to the company's deteriorating financial trajectory and the stock's -36.9% 90-day decline presents a pattern worth tracking closely.

CTO Tsai Philip bought 21,000 shares at $9.43; stock -59.2% from 52-week high. Cluster buy pattern with 2 other insiders in 14 days.

Philip Tsai, Chief Technology Officer, established an initial position of 21,000 shares at $9.43 on 2024-11-21, totaling $198,030.00. This purchase occurs as IMNM trades at $11.15, down -59.2% from its 52-week high of $27.34 and -25.5% over the trailing 90 days. Notably, this buy is part of a cluster pattern: 2 other insiders also purchased within the past 14 days, suggesting coordinated confidence at depressed price levels. However, context is essential: the company reported a net loss of $47,100,000.00 against quarterly revenue of $2,910,000.00, indicating significant operational challenges that may warrant independent verification of the drivers behind this insider buying activity.